Glina Sidney, Sotomayor Mariano, Gatchalian Eduardo, Yaman Onder, Dyachkova Yulia, Markey Caroline, Kopernicky Vladimir
Department of Urology, Ipiranga Hospital, Sao Paulo, Brazil.
J Sex Med. 2006 Mar;3(2):309-19. doi: 10.1111/j.1743-6109.2006.00220.x.
Tadalafil, a phosphodiesterase type 5 inhibitor, has an extended period of effectiveness, up to 36 hours, for the treatment of erectile dysfunction (ED). Changes in behavior of long-term sildenafil users were evaluated by assessing time of dose relative to sexual intercourse attempts during treatment with sildenafil and tadalafil.
This open-label study was conducted in men with ED and a history of >or=6-week prior sildenafil use in Australia, New Zealand, Asia, Central and Eastern Europe, the Middle East, and Latin America. Patients continued sildenafil treatment for 4 weeks, then switched to tadalafil for 8 weeks. Timing of sexual intercourse attempt relative to dose was assessed through patient diaries for the final 4 weeks of each treatment period. Patients continued their treatment of choice in an extension period.
A total of 2,760 men (mean age 54.4 years) with a median duration of prior sildenafil use of 474 days were enrolled. Significant increases in median time from dose to intercourse attempt were observed when changing treatment from sildenafil citrate (1.21 hours) to tadalafil (3.25 hours; P < 0.001). Fifty-nine percent of intercourse attempts were within 4 hours of dosing when patients were treated with tadalafil (88% with sildenafil). The proportion of intercourse attempts per patient made >4 hours after dose was considerably higher during the tadalafil than during the sildenafil assessment period. Similar daily cycles of frequency of dosing and intercourse attempts were observed in all study periods and were characterized by a small peak in the morning and a large peak in the evening. When changing treatment to tadalafil, patients administered the drug earlier in the day and over a broader period of time.
Following the dosing instructions reflecting tadalafil's extended period of effectiveness, men with a history of established sildenafil use changed their dose-attempt behavior when treated with tadalafil.
他达拉非是一种5型磷酸二酯酶抑制剂,对勃起功能障碍(ED)的治疗具有长达36小时的延长疗效期。通过评估在用西地那非和他达拉非治疗期间剂量时间与性交尝试时间的关系,来评价长期使用西地那非患者的行为变化。
这项开放标签研究在澳大利亚、新西兰、亚洲、中东欧、中东和拉丁美洲患有ED且有≥6周西地那非使用史的男性中进行。患者继续服用西地那非治疗4周,然后改用他达拉非治疗8周。通过患者日记评估每个治疗期最后4周性交尝试相对于剂量的时间。患者在延长期继续其选择的治疗。
共纳入2760名男性(平均年龄54.4岁),先前西地那非使用的中位持续时间为474天。当治疗从枸橼酸西地那非(1.21小时)改为他达拉非(3.25小时;P<0.001)时,观察到从给药到性交尝试的中位时间显著增加。当患者接受他达拉非治疗时,59%的性交尝试发生在给药后4小时内(西地那非治疗时为88%)。在他达拉非评估期,每位患者在给药后>4小时进行的性交尝试比例明显高于西地那非评估期。在所有研究期均观察到类似的给药频率和性交尝试的每日周期,其特征是早晨有一个小高峰,晚上有一个大高峰。当改为他达拉非治疗时,患者在一天中更早且在更宽的时间段内给药。
遵循反映他达拉非延长疗效期的给药说明,有西地那非使用史的男性在接受他达拉非治疗时改变了他们的剂量-尝试行为。